• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva Pharmaceuticals launches generic Erythromycin tablets in U.S.

May 4, 2021 By Sean Whooley

TevaTeva Pharmaceuticals (NYSE:TEVA) announced today that it launched generic Erythromycin oral tablets in the U.S.

Parsippany, N.J.-based Teva — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries — launched the 250 mg- and 500 mg-strength generic Erythromycin tablets, which are a therapeutic equivalent for the reference listed drug Erythromycin from Arbor Pharmaceuticals, according to a news release.

Teva’s generic Erythromycin tablets are indicated for treating a number of bacterial infections and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.

Erythromycin treats infections caused by specific, susceptible strains of microorganisms in diseases including respiratory tract infections, listeriosis, skin and skin structure infections, pertussis (whooping cough), diphtheria, erythrasma, intestinal amebiasis, acute pelvic inflammatory disease, conjunctivitis in newborns, pneumonia of infancy, urogenital infections during pregnancy, uncomplicated urethral, endocervical, or rectal infections in adults in specific situations; nongonococcal urethritis in specific situations, primary syphilis and Legionnaires’ Disease.

Teva said IQVIA data from January 2021 claims that U.S. sales of Erythromycin oral tablets total more than $49 million annually.

Filed Under: Business/Financial News, Featured, Pharmaceuticals Tagged With: Teva, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS